

Remarks

Claims 34-40 and 47-49 are pending in the subject application. By this Amendment, Applicants have amended claim 37. Support for the amendments can be found throughout the subject specification and in the claims as originally filed (see, for example, page 48, lines 22-24, of the specification). Entry and consideration of the amendments presented herein is respectfully requested. Accordingly, claims 34-40 and 47-49 are currently before the Examiner. Favorable consideration of the pending claims is respectfully requested.

As an initial matter, Applicants gratefully acknowledge the Examiner's withdrawal of the objections to the specification and the rejection under 35 U.S.C. §102(b) over Pan *et al.*

Claims 37, 40, and 49 are rejected under 35 U.S.C. § 112, second paragraph, as indefinite. The Office Action indicates that the recitation of the limitation "at least six consecutive amino acids ... spans positions 92 and 98" causes the claim to be vague and indefinite. Applicants respectfully submit that claim 37 is not vague or indefinite. Applicants respectfully submit that the plain reading of the claim indicates that the claimed fragment is at least six consecutive amino acids of SEQ ID NO: 58 and that the fragment contains at least six of the amino acids located at positions 92 through 98 of SEQ ID NO: 58. However, in the interest of expediting prosecution in this matter, Applicants have amended claim 37 in a fashion that renders this issue moot. Accordingly, reconsideration and withdrawal of the rejection under 35 U.S.C. § 112, second paragraph, is respectfully requested.

Claims 37, 40, and 49 are rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. Applicants respectfully assert that there is adequate written description in the subject specification to convey to the ordinarily skilled artisan that they had possession of the claimed invention; however, in the interest of expediting prosecution in this matter, Applicants have amended claim 37 to delete the limitation of "fragment spans positions 92 and 98 of SEQ ID NO: 58" thereby rendering this rejection moot. Accordingly, reconsideration and withdrawal of the rejection under 35 U.S.C. § 112, first paragraph, is respectfully requested.

Claims 34-49 are rejected under 35 U.S.C. § 101 and 35 U.S.C. § 112, first paragraph, on the ground that the claimed invention is not supported by a well-established utility. The Office Action

argues that the utilities indicated within the specification are non-specific or particular to the claimed sequence. For example, the Office Action argues that the use of the claimed sequence as a substrate for various proteases, in animal models, for the diagnosis of diseases or disorders associated with abnormalities of the metabolism of collagen or the monitoring of collagen degradation are non-specific uses that are applicable to a large family of structurally related collagen related proteins and which are not specific to the polypeptide being claimed. Applicants, again, respectfully traverse.

The examiner bears the initial burden of showing that a claimed invention lacks patentable utility. *See In re Brana*, 51 F.3d 1560, 1566, 34 USPQ2d 1436, 1441 (Fed. Cir. 1995) (“Only after the PTO provides evidence showing that one of ordinary skill in the art would reasonably doubt the asserted utility does the burden shift to the applicant to provide rebuttal evidence sufficient to convince such a person of the invention’s asserted utility.”). It is respectfully submitted that the Office Actions issued in this matter have failed to provide any evidence showing that the asserted utility would be doubted by those of ordinary skill in the art.

In the initial Office Action, the Patent Office argued that the asserted utilities of the claimed polypeptide was not credible, specific, or substantial on the grounds that the paper first reporting the isolation of the human alpha 1 type XVI collagen (also known as COL16A1) authored by Pan *et al.* in 1992 states that “structural similarities between the  $\alpha 1$  type XVI collagen and the FACIT group raise the intriguing possibility that the  $\alpha 1$  (XVI) collagen may serve similar functions”. This position has been maintained in the subsequent Office Action.

Applicants respectfully submit that the Office Actions fail to take into account further information developed with regards to  $\alpha 1$  type XVI collagen after the publication of Pan *et al.* For example, a number of splice variants of the human alpha 1 type XVI collagen are known (see attached EMBL-EBI Altsplice printout indicating eleven (11) known splice variants). Additionally, review texts documenting the state of the art for what the authors termed “unconventional collagens” (including human alpha 1 type XVI collagen) have been written (see *Unconventional Collagens Types VI, VII, VIII, IX, X, XIV, XVI and XIX*, S. Ricard-Blum *et al.*, Oxford Press, 2000, attached hereto), and, as indicated in the attached ENTREZ PROTEIN and ENTREZ GENE printouts, members of this collagen family are found in association with fibril-forming collagens such as type I and II and serve to maintain the integrity of the extracellular matrix. Finally, high levels of type XVI

collagen have been found in fibroblasts and keratinocytes, and in smooth muscle and amnion. Thus, it is respectfully submitted that the Patent Office has failed to show that one skilled in the art would reasonably doubt the utilities asserted with respect to the claimed polypeptide, particularly in view of the knowledge regarding such polypeptides that was gathered subsequent to the publication of Pan *et al.*

As set forth in the specification, the instantly claimed invention has utility for: the diagnosis of diseases or disorders associated with abnormalities of the metabolism of collagen; use in assays (*in vitro*) as a substrate of proteases; the treatment of diseases and conditions associated with collagen matrix destruction, including for wound treatment; for preparing cosmetic compositions such as skin creams with anti-wrinkle activity; or use as an injectable biomaterial. Applicants respectfully submit that the fact that the claimed polypeptide has certain uses that overlap with other structurally related proteins (collagens) is not controlling as to whether the claimed polypeptide has a utility that is specific, credible, substantial or well-established. For example, the subject specification indicates that the claimed polypeptide can be used as an injectable biomaterial or in cosmetic compositions. As the Patent Office may be aware, injectable collagen is used in the fields of plastic surgery for a variety of purposes, including for lip augmentation and to rectify facial defects, frown lines and acne scars (see paragraph 983 of the published application). Thus, it is respectfully submitted that one skilled in the art would recognize that the instantly claimed invention would have a specific, credible, substantial and well-established utility for use in the field of plastic surgery as an injectable composition. Further, it is respectfully submitted that one skilled in the pertinent arts would be able to use the subject invention in view of the teachings of the application and/or the skill/knowledge of the artisan of the relevant field of endeavor. Accordingly, reconsideration and withdrawal of the rejections is respectfully requested.

Claims 37, 40, and 49 are rejected under 35 U.S.C. § 102(b) as anticipated by Olsen *et al.* (1999). The Office Action states that the Olsen *et al.* reference discloses a collagen polypeptide fragment comprising at least six consecutive amino acids which spans positions 92 and 98 of SEQ ID NO: 58. Applicants respectfully submit that the cited reference does not anticipate the presently claimed invention. However, by this Amendment, Applicants have amended claim 37 to delete the limitation of “fragment spans positions 92 and 98 of SEQ ID NO: 58” thereby rendering this

rejection moot. Accordingly, reconsideration and withdrawal of the rejection under 35 U.S.C. § 102(b) is respectfully requested.

It should be understood that the amendments presented herein have been made solely to expedite prosecution of the subject application to completion and should not be construed as an indication of Applicants' agreement with or acquiescence in the Examiner's position. Applicants expressly reserve the right to pursue the invention(s) disclosed in the subject application, including any subject matter canceled or not pursued during prosecution of the subject application, in a related application.

In view of the foregoing remarks and amendments to the claims, Applicants believe that the currently pending claims are in condition for allowance, and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Applicants invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachments: EMBL-EBI Altsplice printout

*Unconventional Collagens Types VI, VII, VIII, IX, X, XIV, XVI and XIX*, S. Ricard-

Blum *et al.*, Oxford Press, 2000, abstract only

ENTREZ PROTEIN and ENTREZ GENE printouts



Get  Nucleotide sequences  for   ? Site search



[EBI Home](#)
[About EBI](#)
[Groups](#)
[Services](#)
[Toolbox](#)
[Databases](#)
[Downloads](#)
[Submissions](#)

Wrapper Query Page

## ASD AltSplice Entry Display

[Help](#)

### Altsplice-Human : Entry ENSG00000084636

#### GENE INFORMATION :

Gene symbols : COL16A1 , 447AA , FP1572  
 Protein description : Collagen alpha 1(XVI) chain precursor.  
 [Source:Uniprot/SWISSPROT;Acc:Q07092]  
 Gene sequence : [View the gene sequence](#)

#### CHROMOSOME INFORMATION :

Chromosome : 1  
 Contig start-end : 31783941 - 31841742  
 Strand : Minus

#### CROSS REFERENCES :

EnsEMBL gene : ENSG00000084636  
 EnsEMBL Transcript/Peptide : ENST00000271069 (ENSP00000271069.5)  
 Uniprot/SwissProt : Q07092  
 EMBL : M92642 , S57132  
 REFSEQ : NP\_001847 , NM\_001856  
 GO : GO:0007155 , GO:0007565 , GO:0006817 , GO:0005201 , GO:0005737 ,  
 GO:0005578 , GO:0005597  
 PROTEIN ID : AAA58427 , AAB25797  
 INTERPRO : IPR003979 , IPR000694 , IPR002965 , IPR008160


#### GENE ONTOLOGY :

MOLECULAR FUNCTION : structural molecule activity ; extracellular matrix structural  
 constituent : ( GO:0005201 )  
 extracellular region ; extracellular matrix (sensu Metazoa) :  
 ( GO:0005578 )

CELLULAR COMPONENT :	extracellular region ; extracellular matrix (sensu Metazoa) ; collagen : ( GO:0005597 ) cell ; intracellular ; cytoplasm : ( GO:0005737 )
BIOLOGICAL PROCESS :	physiological process ; cellular physiological process ; transport : ( GO:0006817 ) physiological process ; organismal physiological process ; reproductive physiological process : ( GO:0007565 ) cellular process ; cell communication ; cell adhesion : ( GO:0007155 )

EVIDENCES :	
Human-Mouse Conservation :	o Intron/Exon level ENSMUSG00000040690

Confirmed introns/exons :	<a href="#">Click on this link displays a page giving reference transcript structure and confirmed introns/exons</a>
---------------------------	--



<a href="#">CLICK HERE FOR ADDITIONAL FUNCTIONALITIES</a>
<b>Splice Pattern Viewer</b>

**Legend : A dashed line between features indicates a gap on the pattern where an intron couldn't be fully confirmed.**

**numl: number of libraries that confirm this pattern.**

**SP: indicates the index of the splice pattern. Putting the mouse pointer over a "SP" text ("mouse-over") brings up a pop-up window with expression state information, links to splice pattern table (with the appropriate splice pattern as high-lighted) along with expression state information and pattern sequence.**

**Putting the mouse pointer over an exon/intron feature brings up a pop-up window with link to sequence page of the feature.**

Splice patterns on  
Ensembl browser

Show Splice Patterns along the contig via Ensembl  
DAS source

How do I set the DAS server  
up for the first time ?

Splice Pattern Table					
PATTERN SEQUENCE	PEPTIDE SEQUENCE	STRUCTURE	CONFIRMING EST/mRNA's	CLONE LIBRARIES	IDENTIFIED SNP's
1		~37048..37238, 38194..38247, 38831..38884, 39421..39474, 40968..41012, 41114..~41168, ~41431..41466, 41815..41877, 44391..44462, 44662..44715, 45345..~45384	4	4	19
2		~45352..45389, 45591..45635, 45930..45983, 46411..46464, 48085..48135, 48472..48561, 49981..50016, 50605..50649, 51547..~51736	3	3	11
3		~45928..45983, 46411..46464, 48085..48135, 48472..48561, 49981..50016, 50605..50649, 51547..51735, 52191..52257, 53006..~53145	2	1	15
4		~49981..50016, 50605..50649, 51547..51735, 52191..52257, 53006..53182, 53373..53450, 54196..~54237	16	14	12
5	4856.9125 (211 aa)	~3184..3212, 4822..4928, 6934..7008, 7119..~7236, ~8445..8566, 8877..~9143	7	5	11
6		~8465..8566, 8877..9143, 9749..9829, 9961..10086, 10908..~10963	1	1	4
7		~40664..41012, 41114..~41168, ~41431..41466, 41815..41877, 44391..~44462	1	1	4
8		~20768..20805, 20914..20958, 21279..21410, 22193..~22229	3	2	3

9	~2989..3212, 6934..7008, 7119..~7236	1	1	7
10	~36406..36493, 38194..38247, 38831..~38885	1	1	7
11	~51201..51735, 52191..52257, 53006..~53183	2	2	5


o View all the splice pattern sequences

## **Splice Events :**



Cassette Exon Event			
CASSETTE EXON(s)	EVENT TYPE	AEDB ASSOCIATION	CONSERVATION
4822..4928	SCE		

[Home](#)

Please contact [EBI Support](#) with any problems or suggestions regarding this site.

 [View Printer-friendly version of this page](#) | [Terms of Use](#)





All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for

Limits Preview/Index History Clipboard Details

Display Abstract  20

All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
Special Queries  
LinkOut  
My NCBI

Related Resources

Order Documents  
NLM Mobile  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

☐ 1: J Cell Sci. 2000 Dec;113 (Pt 23):4141-2.

Related Articles, Links




## Unconventional collagens

### Knight DP.

Unconventional Collagens Types VI, VII, VIII, IX, X, XIV, XVI and XIX by S. Ricard-Blum, B. Dublet and M. van der Rest Oxford University Press (2000) pp.155. ISBN 0-19-850545-0 35.00 This thoroughly researched monograph in Oxford University Press's 'Protein Profile Series' reviews substantially all the significant literature on this interesting and highly important group of proteins. The authors use the term 'Unconventional Collagens' for the collagens of higher vertebrate connective tissues which do not, of themselves, form classical fibrils with a 68 nm banding pattern. The authors chose to omit type IV collagen as this, they claim, would have almost doubled the size of the volume. The monograph represents a very considerable achievement in three respects. Firstly it comprehensively reviews the literature on the sequence, structure, expression, post-translational modification, genetics, physiological function and pathology of each separate unconventional collagen. The thoroughness of this review is indicated by the fact that the bibliography contains no fewer than 1196 references. Secondly, the monograph identifies the modular domain structure for each collagen, clearly demonstrating that these proteins are block co-polymers mainly derived in evolution from a small number of ancestral genes. Thirdly, it starts to identify the way in which the different modules of these sticky molecules interact with each other and with other connective tissue components. This is an important start if we are to understand their vital role in the self-assembly processes which occur in embryology, tissue repair and the major degenerative and collagen gene diseases. The clearly written and well set out text is supported by excellent micrographs of rotary shadowed molecules and molecular aggregates and a wealth of diagrams and tables. The book has, in my view, three minor shortcomings: a short summary chapter on type IV would enable the non-specialist reader to relate this collagen to the other non-conventional collagens. Concise summaries at the ends of each chapter would orient newcomers to the field. More significantly, apart from the brief introduction, the book lacks an overall synthesis which pulls together the findings of the separate chapters. These slight limitations aside, this book is essential reading for those engaged in connective tissue research and will do much to stimulate further activity in this area. It will also be of considerable interest to tissue engineers, pathologists and embryologists.

PMID: 0011069758 [PubMed - as supplied by publisher]

Display Abstract  20



PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search Protein

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display GenPept



Show 5



Send to

Range: from begin

to end

Features:



SNP



CDD



MGC



HPRD



STS



tRNA

Refresh

☐ 1: NP\_001847. Reports alpha 1 type XVI ...[gi:18641352]

BLink, Conserved  
Domains, Links

LOCUS NP\_001847 1603 aa linear PRI 16-OCT-2005  
 DEFINITION alpha 1 type XVI collagen precursor [Homo sapiens].  
 ACCESSION NP\_001847  
 VERSION NP\_001847.2 GI:18641352  
 DBSOURCE REFSEQ: accession NM\_001856.2  
 KEYWORDS .  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;  
 Hominidae; Homo.  
 REFERENCE 1 (residues 1 to 1603)  
 AUTHORS Kassner,A., Tiedemann,K., Notbohm,H., Ludwig,T., Morgelin,M.,  
 Reinhardt,D.P., Chu,M.L., Bruckner,P. and Grassel,S.  
 TITLE Molecular structure and interaction of recombinant human type XVI  
 collagen  
 JOURNAL J. Mol. Biol. 339 (4), 835-853 (2004)  
 PUBMED 15165854  
 REMARK GeneRIF: interacts with fibrillin-1 and with fibronectin indicating  
 multiple molecular interactions in which this ubiquitously  
 expressed and versatile fibril-associated collagens with  
 interrupted triple helices-collagen can participate  
 REFERENCE 2 (residues 1 to 1603)  
 AUTHORS Kassner,A., Hansen,U., Miosge,N., Reinhardt,D.P., Aigner,T.,  
 Bruckner-Tuderman,L., Bruckner,P. and Grassel,S.  
 TITLE Discrete integration of collagen XVI into tissue-specific collagen  
 fibrils or beaded microfibrils  
 JOURNAL Matrix Biol. 22 (2), 131-143 (2003)  
 PUBMED 12782140  
 REMARK GeneRIF: Not in banded collagen fibrils in dermis, but is component  
 of specialized fibrillin-1-containing microfibrils. In cartilage  
 matrix not in aggregates with fibrillin-1. Resides in thin, weakly  
 banded collagen fibrils also containing collagens II and XI.  
 REFERENCE 3 (residues 1 to 1603)  
 AUTHORS Grassel,S., Timpl,R., Tan,E.M. and Chu,M.L.  
 TITLE Biosynthesis and processing of type XVI collagen in human  
 fibroblasts and smooth muscle cells  
 JOURNAL Eur. J. Biochem. 242 (3), 576-584 (1996)  
 PUBMED 9022684  
 REFERENCE 4 (residues 1 to 1603)  
 AUTHORS Sires,U.I., Dublet,B., Aubert-Foucher,E., van der Rest,M. and  
 Welgus,H.G.  
 TITLE Degradation of the COL1 domain of type XIV collagen by 92-kDa  
 gelatinase  
 JOURNAL J. Biol. Chem. 270 (3), 1062-1067 (1995)  
 PUBMED 7836360  
 REFERENCE 5 (residues 1 to 1603)  
 AUTHORS Yamaguchi,N., Kimura,S., McBride,O.W., Hori,H., Yamada,Y.,  
 Kanamori,T., Yamakoshi,H. and Nagai,Y.  
 TITLE Molecular cloning and partial characterization of a novel collagen

chain, alpha 1(XVI), consisting of repetitive collagenous domains and cysteine-containing non-collagenous segments

JOURNAL J. Biochem. 112 (6), 856-863 (1992)  
 PUBMED [1284248](#)  
 REFERENCE 6 (residues 1 to 1603)  
 AUTHORS Pan,T.C., Zhang,R.Z., Mattei,M.G., Timpl,R. and Chu,M.L.  
 TITLE Cloning and chromosomal location of human alpha 1(XVI) collagen  
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 89 (14), 6565-6569 (1992)  
 PUBMED [1631157](#)  
 COMMENT REVIEWED REFSEQ: This record has been curated by NCBI staff. The reference sequence was derived from [M92642.1](#) and [R54778.1](#). On Feb 8, 2002 this sequence version replaced [gi:11386159](#).

Summary: This gene encodes the alpha chain of type XVI collagen, a member of the FACIT collagen family (fibril-associated collagens with interrupted helices). Members of this collagen family are found in association with fibril-forming collagens such as type I and II, and serve to maintain the integrity of the extracellular matrix. High levels of type XVI collagen have been found in fibroblasts and keratinocytes, and in smooth muscle and amnion.

FEATURES Location/Qualifiers

source 1..1603  
 /organism="Homo sapiens"  
 /db\_xref="taxon:9606"  
 /chromosome="1"  
 /map="1p35-p34"

Protein 1..1603  
 /product="alpha 1 type XVI collagen precursor"  
 /note="collagen XVI, alpha-1 polypeptide; alpha 1 type XVI collagen"

sig\_peptide 1..21  
 /calculated\_mol\_wt=2386

mat\_peptide 22..1603  
 /product="alpha 1 type XVI collagen"  
 /calculated\_mol\_wt=155312

CDS 1..1603  
 /gene="COL16A1"  
 /coded\_by="NM\_001856.2:247..5058"  
 /note="go\_component: cytoplasm [goid [0005737](#)] [evidence IEA];  
 go\_component: collagen type XVI [goid [0005597](#)] [evidence TAS] [pmid [1284248](#)];  
 go\_component: extracellular matrix (sensu Metazoa) [goid [0005578](#)] [evidence IEA];  
 go\_function: structural molecule activity [goid [0005198](#)] [evidence IEA];  
 go\_process: cell adhesion [goid [0007155](#)] [evidence IEA];  
 go\_process: pregnancy [goid [0007565](#)] [evidence TAS] [pmid [1284248](#)];  
 go\_process: phosphate transport [goid [0006817](#)] [evidence IEA]"  
 /db\_xref="GeneID:1307"  
 /db\_xref="HGNC:2193"  
 /db\_xref="HPRD:00381"  
 /db\_xref="MIM:120326"

## ORIGIN

```

1  mwvswapglw llglwatfgh gantgaqcpp sqqeglkleh ssslpanvtg fnlihrslsm
61  kksaikkirn pkgplilrlg aapvtqptrr vfprglpeef alvltlllkk hthqktwylyf
121 qvtdangypq islevnsqer slelraaggqd gdfvscifpv pqlfdlrwhk lmlsvagrva
181 svhvdcssas sqplgprrpm rpvgfhvflgl daeqgkpvsf dlqqvhiycd pelvleegcc
241 eilpagcppe tskarrrdtqs nelieinpqs egkvytrcfc leepqnsevd aqltgrisqk
301 aergakvhqe taadeccppcv hgardsnvtl apsgpkggkg erglpgppeg kgekargnd
361 cvrispdapl qcaegpkgek gesgalgpsg lpgstgekkg kgekdggek gvpgkpgrdg
421 pgeicvigpk gqkgdpgfvq peglagepgp pglpgppgig lpgtpgdpgg ppgpkgdkg
481 sgipgkegpg gkpgkpgvk gkdpcevcp tlpegfqnfv glpgkpgpgk epgdpvrarg

```

```
541 dpqiaggikge kgepclscss vvaqhlvss tgasgdvgsf gfglpglpgr agvpglkgek
601 gnfgaeagpag spgppgpvpv agikgakgep cepcpalsnl qdgdvrval pppsgekgep
661 gppgfglpgk qgkagerglk gqkgdagnpg dpgtpgttgr pglsgpegvq gpagpkgek
721 dgctacpslq gtvtmagrp gqpgpkgeqg pegvgrpgkp gqpglpqvqg ppglkgvqge
781 pggpgrgvqg pqgepgapgl pgiqglpgr gppgptgek aqgspgvka tgpvgppgas
841 vsgppgrdgq qgqtglrgtp gekgrgek epgecscpsq gdliifsgmpg apglwmgssw
901 qpgpqgppgi pggppgpvp glqgvpgnng lpgqpgltae lgsllpiehl lksicgdcvq
961 gqrahpgylv ekgekqdqi pgvpglndca qcflslerpr aeeargdnse gdpvcvsgp
1021 lpgppglpgq rgeegppgmr gspgpppgi ppgfpgavgs pglpglqger gltgltgdkg
1081 epggpgqpy pgatgppglp gikgergytg sagekgepg psglpgpp gpagprgerg
1141 pqgnsgekqd qgfqqpgft gptgspgfp kvsgpppgp qakgsegir ppsglpgspg
1201 ppgppgiagg agldgldgkd gkpglrgdp pagppglmgp pgfkgtghp glpgpkgdcg
1261 kpgppgstgr pgaegepgam gpqgrpgpg hvpgpppgp ppgagisav lkgdratge
1321 rglaglpqp gppghpgpp epgtgaagk egpgkqgy gppgpkgdp aagkqgqage
1381 kgragmpggp gksqsmgvp ppgpgergh pgapgpsgp glpgvpqsmg dmvnydeikr
1441 firgeiikmf dermayytsr mqfpmemaaa pgrpgppgkd gapgrpgap spglpgqigr
1501 egrqglpvr glpgtkgek digigiagen glpgpppgp ppgykgmat gpmgqqqipg
1561 ipggpgpmgq pgkaghcnp dcfgampme qyppmktmk pfg
```

//

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)



All Databases

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Books

OMIM

Search Gene



for

Go

Clear

☒ current records only

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

Display Full Report



Show 5



Send to

☒ All: 1 Genes Genomes: 1 SNP GeneView: 1 

☐ 1: COL16A1 collagen, type XVI, alpha 1 [*Homo sapiens*]

GeneID: 1307 Locus tag: HGNC:2193; MIM: 120326

updated 03-Nov-2005

## Summary

**Official Symbol:** COL16A1 and **Name:** collagen, type XVI, alpha 1 provided by HUGO

[Gene Nomenclature Committee](#)
**Gene type:** protein coding

**Gene name:** COL16A1

**Gene description:** collagen, type XVI, alpha 1

**RefSeq status:** Reviewed

**Organism:** *Homo sapiens*
**Lineage:** *Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; Homo*
**Gene aliases:** 447AA; FP1572

**Summary:** This gene encodes the alpha chain of type XVI collagen, a member of the FACIT collagen family (fibril-associated collagens with interrupted helices). Members of this collagen family are found in association with fibril-forming collagens such as type I and II, and serve to maintain the integrity of the extracellular matrix. High levels of type XVI collagen have been found in fibroblasts and keratinocytes, and in smooth muscle and amnion.

## Genomic regions, transcripts, and products

(minus strand) [RefSeq below](#)


NC\_000001



## Genomic context

[See COL16A1 in MapViewer](#)

chromosome: 1; Location: 1p35-p34



## Bibliography

Gene References into Function (GeneRIF): [Submit](#)
[PubMed links](#)
**GeneRIFs:**

1. interacts with fibrillin-1 and with fibronectin indicating multiple molecular interactions in which this ubiquitously expressed and versatile fibril-associated collagens with interrupted triple helices-collagen can participate

[PubMed](#)

2. Not in banded collagen fibrils in dermis, but is component of specialized

[PubMed](#)
[Entrez Gene Home](#)

### Table Of Contents

Summary  
 Genomic regions, transcripts...  
 Genomic context  
 Bibliography  
 General gene information  
 General protein information  
 Reference Sequences  
 Related Sequences  
 Additional Links

### Links

Conserved Domains  
 Genome  
 GEO Profiles  
 HomoloGene  
 Map Viewer  
 Nucleotide  
 OMIM  
 Full text in PMC  
 Probe  
 Protein  
 PubMed  
 PubMed (GeneRIF)  
 SNP  
 SNP: Genotype  
 SNP: GeneView  
 Taxonomy  
 UniSTS  
 AceView  
 Ensembl  
 Evidence Viewer  
 GDB  
 HGNC  
 HPRD  
 KEGG  
 ModelMaker  
 UCSC  
 UniGene  
 LinkOut

### Entrez Gene Info

[Feedback](#)
[Subscriptions](#)

fibrillin-1-containing microfibrils. In cartilage matrix not in aggregates with fibrillin-1. Resides in thin, weakly banded collagen fibrils also containing collagens II and XI.

## General gene information



### Markers

**STS-W96115**(e-PCR) (Links: [UniSTS: 25967](#))

Alternate names: RH76723; sts-W96115

**SHGC-35321**(e-PCR) (Links: [UniSTS: 45868](#))

Alternate names: RH38648; RH50395; SGC35321

**G15937**(e-PCR) (Links: [UniSTS: 72120](#))

Alternate names: CHLC.UTR\_03582\_S57132; CHLC.UTR\_03582\_S57132.P65059

**RH69199**(e-PCR) (Links: [UniSTS: 73013](#))

Alternate name: M92642

**STS-M92642**(e-PCR) (Links: [UniSTS: 73133](#))

Alternate names: RH76257; sts-M92642

### GeneOntology

Provided by [GOA](#)

#### Function

[structural molecule activity](#)

#### Evidence

IEA

#### Process

[cell adhesion](#)

IEA

[phosphate transport](#)

IEA

[pregnancy](#)

TAS [PubMed](#)

#### Component

[collagen type XVI](#)

TAS [PubMed](#)

[cytoplasm](#)

IEA

[extracellular matrix \(sensu Metazoa\)](#)

IEA

### Homology:

#### Mouse, Rat

[Map Viewer](#)

## General protein information



**Names:** alpha 1 type XVI collagen

alpha 1 type XVI collagen; collagen XVI, alpha-1 polypeptide

## NCBI Reference Sequences (RefSeq)



**mRNA Sequence** [NM\\_001856](#)

**Source Sequence** [M92642](#),[R54778](#)

**Product** [NP\\_001847](#) alpha 1 type XVI collagen precursor

**Conserved Domains** (1) [summary](#)

[smart00210: TSPN; Thrombospondin N-terminal -like domains](#)

Location: 50 - 231 Blast Score: 419

## Related Sequences



#### Nucleotide

**mRNA** [AB209571](#)

#### Protein

[BAD92808](#)

**mRNA** [AF370368](#)

[AAQ15204](#)

**mRNA** [M92642](#)

[AAA58427](#)

**mRNA** [R54778](#)

None

**mRNA** [S57132](#)

[AAB25797](#)

mRNA	<a href="#">X14963</a>	<a href="#">CAA33085</a>
mRNA	<a href="#">X15038</a>	<a href="#">CAA33142</a>
	None	<a href="#">Q07092</a>
		<a href="#">Q16593</a>
		<a href="#">Q59F89</a>
		<a href="#">Q71RG9</a>

---

**Additional Links**[UniGene Hs.368921](#)[MIM 120326](#)[HPRD 00381](#)Display [Full Report](#)

Show 5



Send to



[Restrictions on Use](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)